Catalyst Pharmaceuticals (CPRX) Cost of Revenue (2019 - 2026)

Catalyst Pharmaceuticals has reported Cost of Revenue for 8 years, with the latest figure at $14.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 19.18% year-over-year to $14.5 million; the trailing twelve-month figure through Mar 2026 stood at $83.8 million (up 12.91% YoY), and the FY2025 full-year result was $87.3 million, up 26.74% from the prior year.
• Cost of Revenue for Q1 2026 stood at $14.5 million, down from $26.1 million in the prior quarter.
• The five-year high for Cost of Revenue was $26.1 million in Q4 2025, with the low at $5.9 million in Q1 2022.
• Historically, Cost of Revenue has averaged $15.1 million across 5 years, with a median of $14.5 million in 2026.
• Annual changes were most pronounced in 2022 — Cost of Revenue soared 82.02% — and 2026, when it declined 19.18%.
• Catalyst Pharmaceuticals' Cost of Revenue stood at $11.2 million in 2022, then surged by 41.21% to $15.8 million in 2023, then surged by 36.9% to $21.6 million in 2024, then climbed by 20.47% to $26.1 million in 2025, then slumped by 44.48% to $14.5 million in 2026.
• The last three Cost of Revenue figures came in at $14.5 million (Q1 2026), $26.1 million (Q4 2025), and $22.7 million (Q3 2025), per Business Quant data.